Institute of Cancer Research, United Kingdom clinical trials
Listed in the registry as: University, hospital or other organization.
The registry lists 113 studies whose lead sponsor is Institute of Cancer Research, United Kingdom. 27 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 8, 2026.
Keep track of what changes. Save the Institute of Cancer Research, United Kingdom studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesFocus areas
Conditions Institute of Cancer Research, United Kingdom leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 113. Browse all 113 →
- Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate CancerRecruitingNCT07002320Phase 1/2
- Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLCRecruitingNCT07718243Phase 1/2
- Understanding the Genetic and Biological Factors That Influence Cancer Treatment Response and Resistance in Patients With Advanced Solid Tumours Through Sample AnalysisRecruitingNCT07737509
- SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi TherapyRecruitingNCT05990192Phase 2
- The BALANCE Study: BlAck and Mixed Men's Lived Experience With Prostate cANCEr-Diversity in Prostate Cancer PROMS StudyNot yet recruitingNCT07529418
- Deployment and Clinical Evaluation of an AI-powered Digital Oncology Biomarker Tool to guidE Treatment in TNBCNot yet recruitingNCT06396754
- 5G-PEARL: Paxalisib in Malignant Brain TumoursRecruitingNCT07391215Phase 1/2
- The i4i PRODICT® Study: Evaluation of the i4i PRODICT® Test in Different Ethnic Groups (The i4i PRODICT® Study).RecruitingNCT06636526
- The Active Surveillance StudyRecruitingNCT05810467
- 5G-RUBY: Avutometinib and Defactinib in Malignant Brain TumoursRecruitingNCT06630260Phase 1/2
- The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a DNA Repair Gene Mutation.RecruitingNCT05097274
- Precision Medicine in the Prostate Cancer Care PathwayRecruitingNCT04763317
- Combination Study of Antibiotics With Enzalutamide (PROMIZE)RecruitingNCT06126731Phase 1/2
- Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline MutationsRecruitingNCT02705846
- Investigating Idetrexed and Olaparib in Patients With Ovarian CancerRecruitingNCT06976892Phase 1
- PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast CancerRecruitingNCT03740893Phase 2
- The eValuation of Sources of vIBRAtioN for Vibrational Shear Wave elasTographyNot yet recruitingNCT07098819
- The PROFILE Study: Germline Genetic Profiling: Correlation With Targeted Prostate Cancer Screening and TreatmentRecruitingNCT02543905
- The COherence of Scatter Identification and Exclusion Algorithm StudyRecruitingNCT06975579
- PRIMER: Development of Daily Online Magnetic Resonance Imaging for Magnetic Resonance Image Guided RadiotherapyRecruitingNCT02973828
- A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRTRecruitingNCT05613023Phase 3
- Microbiome Molecular CharaterisationRecruitingNCT06423976
- PUMA (Paediatric Osseous Marrow Assessment)RecruitingNCT03466944
- Myeloma Novel Drug Discovery Ver 1.2RecruitingNCT05968417
- Hypofractionated Expedited Radiotherapy for Men With localisEd proState CancerRecruitingNCT04595019Not applicable
- Trial of Pembrolizumab in Metastatic Castration Resistant Prostate CancerRecruitingNCT03506997Phase 2
- Prospective Evaluation of Radiotherapy Using Magnetic Resonance Image Guided TreatmentRecruitingNCT03727698Not applicable
- KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast CancerActive, not recruitingNCT03946202Phase 2
- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)Active, not recruitingNCT02305654Phase 3
- 5G-EMERALD: Amivantamab in Malignant Brain TumoursActive, not recruitingNCT06632236Phase 1
- UK Genetic Prostate Cancer Study: Epidemiology and Molecular Genetics StudiesActive, not recruitingNCT01737242
- ASTEROID: A Trial of ASTX660 in Combination With PembrolizumabActive, not recruitingNCT05082259Phase 1
- POTENT - Tepotinib in Combination With Pembrolizumab in NSCLCActive, not recruitingNCT05782361Phase 1
- Transcriptional Responses as an Indicator of Individualised Responses to Radiation Effects (RTGene 2)Active, not recruitingNCT03809377
- Phase I Trial of Defactinib and VS-6766.Active, not recruitingNCT03875820Phase 1
- ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no LossActive, not recruitingNCT04065269Phase 2
- The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer TreatmentActive, not recruitingNCT02955082Phase 2
- Study of Weekly Radiotherapy for Bladder CancerCompletedNCT01810757Not applicable
- PreOperative Endocrine Therapy for Individualised Care With AbemaciclibActive, not recruitingNCT04584853Phase 3
- The BARCODE 1 Pilot StudyActive, not recruitingNCT03158922
- The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte CancerActive, not recruitingNCT00261456
- Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase InhibitorsCompletedNCT00253422Phase 3
- A Trial of Ipatasertib in Combination With AtezolizumabActive, not recruitingNCT03673787Phase 1/2
- The BARCODE 1 Study (Full Study): The Use of Genetic Profiling to Guide Prostate Cancer Targeted Screening.Active, not recruitingNCT03857477
- Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis TumoursCompletedNCT01726374Phase 3
- A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for NephrectomyCompletedNCT01693822Phase 2
- Combination Study of AZD5069 and Enzalutamide.TerminatedNCT03177187Phase 1/2
- Abiraterone Acetate in Combination With TildrakizumabTerminatedNCT04458311Phase 1/2
- Stereotactic Body Radiotherapy for the Treatment of OPDActive, not recruitingNCT03256981Phase 2/3
- Digital Delivery of Information About Genetic Testing for Breast CancerCompletedNCT04842799Not applicable